AP's Morning BriefPre-market brief · Sun–Fri · 7:30am ET
Subscribe free
Market quotes Loading delayed quotes from TradingView… If they don't appear, closing levels are in each brief.

Quotes may be delayed. SPY, QQQ and DIA are delayed exchange quotes; TSX is delayed; 10-yr yield is the daily FRED rate; gold and WTI are TVC feeds. Quote data and widget by TradingView.

Next brief

Earnings

Revvity jumps 7.84% after third-quarter beat and raised full-year outlook

The life sciences company topped estimates on stronger demand from drug developers and lifted its full-year earnings range.

· AP's Morning Brief

Related RVTY
Image: Arild Vågen, NYSE Broad Street facade, CC BY-SA 4.0

Revvity shares rose sharply on Tuesday after the life sciences and diagnostics company reported third-quarter results that beat Wall Street estimates and raised its full-year outlook.

Follow live markets on X @therealapdult.

Revenue for the quarter came in at $729 million, up from $699 million a year earlier, with pro forma organic revenue growth of 7%, according to the company's release. Adjusted earnings from continuing operations were $1.38 per share, compared with $1.18 a year ago. Analysts had expected about $1.30 per share, according to Investing.com.

The company now expects full-year 2026 pro forma adjusted earnings of $5.40 to $5.45 per share, up from a prior range of $5.30 to $5.40, as CNBC also noted. It sees full-year pro forma revenue of about $2.86 billion and pro forma organic growth of about 5%. On the earnings call, management said the third quarter benefited modestly from some timing items it does not expect to repeat in the fourth quarter. Revvity also plans an investor day on November 13.

Revvity closed at $163.48 on the New York Stock Exchange, up $11.88, or 7.84%, from Monday's close of $151.60, giving back part of a bigger gain. Early in the session the stock reached $171.74, its high for the day and a new 52-week high above the prior peak of $169.06, according to CNBC and Yahoo Finance data. It had traded at $167.28 as of 3:17 p.m. ET.

Update, Nov 3, 2026: An earlier version gave intraday figures as of 3:17 p.m. ET; updated with official closing prices.

Correction, Nov 3, 2026: An earlier version said the stock traded as high as $170.43 earlier in the session; the session high was $171.74.

Sources

  1. Business Wire (Revvity release) — Q3 2026 revenue $729 million vs $699 million a year earlier; 7% pro forma organic revenue growth; adjusted EPS from continuing operations $1.38 vs $1.18; full-year 2026 pro forma revenue about $2.86 billion, pro forma organic growth about 5%, pro forma adjusted EPS $5.40-$5.45; Investor Day November 13, 2026.
  2. CNBC — Revvity shares gained 11% midday Nov. 3, 2026 after raising full-year pro forma adjusted EPS guidance to $5.40 to $5.45 from $5.30 to $5.40.
  3. Investing.com (earnings call transcript) — Q3 beat estimates of $1.30 per share; prior-session price $151.60; Q3 benefited modestly from timing items not expected to repeat in Q4; full-year organic growth about 5%. Prior 52-week high $169.06.
  4. Nasdaq.com quote (RVTY) — RVTY last sale $167.28, net change +15.68, +10.34% as of Nov 3, 2026 3:17 PM ET, market open; implied Nov. 2 regular-session price $151.60.
  5. Yahoo Finance (RVTY chart data) — RVTY Nov 2, 2026 regular-session price $151.60; Nov 3 price $167.28 at about 3:17 PM ET.
  6. Investor's Business Daily — Revvity up more than 12% at 170.43 early Tuesday Nov. 3, 2026 after strong Q3 report and raised 2026 view.
  7. CNBC quote (RVTY) — RVTY official close Nov 3, 2026: $163.48 at 4:00 PM ET, change +11.88 (+7.84%) from Nov 2 close $151.60; session high $171.74 (also 52-week high, dated 11/03/26); open $163.01.
  8. Yahoo Finance historical data (RVTY) — RVTY Nov 3, 2026 close $163.48; Nov 2, 2026 close $151.60; change +11.88, +7.84% (Nasdaq.com showed 163.58; CNBC and Yahoo agree on the official print).